HLB Therapeutics Co.,Ltd. Logo

HLB Therapeutics Co.,Ltd.

Develops innovative drugs for rare eye diseases and brain tumors, with vaccine logistics.

115450 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 정자일로 248, 성남시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's core focus is on its clinical pipeline, which includes RGN-259, a therapeutic candidate for ophthalmic conditions such as Neurotrophic Keratopathy and Dry Eye Disease, and OKN-007 for treating Glioblastoma Multiforme. In addition to its primary research and development activities, the company has diversified business areas that include vaccine distribution and cold chain logistics.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for HLB Therapeutics Co.,Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all HLB Therapeutics Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for HLB Therapeutics Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway NYKD
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland OCS
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea 244460
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea 382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea 476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan 4564
Onxeo Logo
Developing precision-guided therapeutics using small antibodies for complex diseases.
France ALONX
Openedges Technology, Inc. Logo
Semiconductor IP provider of memory subsystem & AI platform IP for AI, HPC, and IoT SoCs.
South Korea 394280
Openjobmetis Logo
Employment agency providing staffing, recruitment, and HR services to companies and job seekers.
Italy OJM
Open Up Group Inc. Logo
Provides staffing and outsourcing of engineers for global manufacturing, IT, and construction sectors.
Japan 2154

Talk to a Data Expert

Have a question? We'll get back to you promptly.